Title of article
Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs): Discovery of capromorelin Original Research Article
Author/Authors
Philip A. Carpino، نويسنده , , Bruce A. Lefker، نويسنده , , Steven M. Toler، نويسنده , , Lydia C. Pan، نويسنده , , John R. Hadcock، نويسنده , , Ewell R. Cook، نويسنده , , Joseph N. Dibrino، نويسنده , , Anthony M Campeta، نويسنده , , Shari L. DeNinno، نويسنده , , Kristin L. Chidsey-Frink، نويسنده , , William A. Hada، نويسنده , , John Inthavongsay، نويسنده , , F. Michael Mangano، نويسنده , , Michelle A. Mullins، نويسنده , , David F Nickerson، نويسنده , , Oicheng Ng، نويسنده , , Christine M. Pirie، نويسنده , , John A. Ragan، نويسنده , , Colin R Rose، نويسنده , , David A. Tess، نويسنده , , et al.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2003
Pages
10
From page
581
To page
590
Abstract
Novel pyrazolinone-piperidine dipeptide derivatives were synthesized and evaluated as growth hormone secretagogues (GHSs). Two analogues, capromorelin (5, CP-424391-18, hGHS-R1a Ki=7 nM, rat pituicyte EC50=3 nM) and the des-methyl analogue 5c (hGHS-R1a Ki=17 nM, rat pituicyte EC50=3 nM), increased plasma GH levels in an anesthesized rat model, with ED50 values less than 0.05 mg/kg iv. Capromorelin showed enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%]. This short-duration GHS was orally active in canine models and was selected as a development candidate for the treatment of musculoskeletal frailty in elderly adults.
Journal title
Bioorganic and Medicinal Chemistry
Serial Year
2003
Journal title
Bioorganic and Medicinal Chemistry
Record number
1302550
Link To Document